Evaluation of magnetic resonance imaging for bladder cancer detection following transurethral resection of bladder tumour (TURBT).
Bladder cancer
Diffusion weighted imaging (DWI)
Magnetic resonance imaging
Staging
Transurethral resection of bladder tumour (TURBT)
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
09
11
2023
accepted:
05
02
2024
revised:
02
02
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
To evaluate the performance of MRI for detection of bladder cancer following transurethral resection of bladder tumour (TURBT). This single-centre retrospective study included forty-one consecutive patients with bladder cancer who underwent bladder MRI after TURBT. Two uroradiologists retrospectively assessed the presence of tumour using bladder MRI with and without DWI (diffusion weighted imaging) using a five-point Likert scale. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated and inter-reader agreement was assessed. Histopathology was used as the reference standard. 24 out of 41 patients (58.5%) had no residual tumour or Tis (carcinoma in situ) after TURBT. Sensitivity, specificity, PPV and NPV for detection of tumour using T1WI (T1-weighted imaging) and T2WI (T2-weighted imaging) was 50.0%, 54.6%, 21.1%, and 81.8%, respectively and for T1WI, T2WI and DWI combined was 100%, 76.5%, 50.0% and 100%, respectively. Overestimation of tumour was more common than underestimation. MRI showed high accuracy for patients in whom there was no residual tumour (78.9%). Inter-reader agreement for tumour detection improved from fair (κ = 0.54) to moderate (κ = 0.70) when DWI was included. Non-contrast MRI with DWI showed high sensitivity and relatively high specificity for detection of residual tumour after TURBT. Inter-reader agreement improved from fair to moderate with the addition of DWI. MRI can be useful after TURBT in order to guide further management.
Identifiants
pubmed: 38717615
doi: 10.1007/s00261-024-04235-6
pii: 10.1007/s00261-024-04235-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIHR Cambridge Biomedical Research Centre
ID : NIHR203312
Organisme : Cancer Research UK Cambridge Institute, University of Cambridge
ID : C197/A16465
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Gandhi N, Krishna S, Booth CM et al (2018) Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int 122(5):744–53. https://doi.org/10.1111/bju.14366
doi: 10.1111/bju.14366
pubmed: 29727910
Babjuk M, Burger M, Capoun O et al (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol Jan;81(1):75–94. https://doi.org/10.1016/j.eururo.2021.08.010
doi: 10.1016/j.eururo.2021.08.010
pubmed: 34511303
Flaig TW, Spiess PE, Abern M et al (2022) NCCN Guidelines insights: bladder cancer, version 2.2022. J Natl Compr Cancer Netw, 20 pp. 866-878
doi: 10.6004/jnccn.2022.0041
Witjes JA, Bruins HM, Carrión A et al (2023) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines, Eur Urol Jan;85(1):17–31. https://doi.org/10.1016/j.eururo.2023.08.016
doi: 10.1016/j.eururo.2023.08.016
Department of Health. NHS Cancer Reform Strategy. 2007.
Independent Cancer Taskforce. Achieving world-class cancer outcomes - a strategy for England 2015–2020. CRUK Website; 2015. Available from: https://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf
National Institute for Clinical Excellence surveillance of bladder cancer: diagnosis and management (NICE guideline NG2). 2019 https://www.nice.org.uk/guidance/ng2/resources/2019-surveillance-of-bladder-cancer-diagnosis-and-management-nice-guideline-ng2-pdf-8716335273925
Shariat SF, Palpattu GS, Karakiewicz PI et al (2007) Discrepancy between clinical and pathologic staging: impact on prognosis after radical cystectomy. Eur Urol 51(1):137–151. https://doi.org/10.1016/j.eururo.2006.05.021
doi: 10.1016/j.eururo.2006.05.021
pubmed: 16793197
Dutta SC, Smith Jr JA, Shappell SB et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol Aug;166(2):490–3.
doi: 10.1016/S0022-5347(05)65969-1
pubmed: 11458053
Harrison S, Briggs T, O’Flynn K. Urology: GIRFT Programme National Specialty Report, 1st ed. NHS England and NHS Improvement. 2018 https://gettingitrightfirsttime.co.uk/wp-content/uploads/2018/07/Urology-June18-M.pdf
Bryan RT, Liu W, Pirrie SJ et al (2021) Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath study. Eur Urol 80:12–5. https://doi.org/10.1016/j.eururo.2021.02.021
doi: 10.1016/j.eururo.2021.02.021
pubmed: 33653635
Panebianco V, Narumi Y, Altun E et al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol Sep;74(3):294–306. https://doi.org/10.1016/j.eururo.2018.04.029
doi: 10.1016/j.eururo.2018.04.029
pubmed: 29755006
pmcid: 6690492
Wang H, Luo C, Zhang F et al (2019) Multiparametric MRI for bladder cancer: Validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 291: 668–674. https://doi.org/ https://doi.org/10.1148/radiol.2019182506
doi: 10.1148/radiol.2019182506
pubmed: 31012814
El-Assmy A, Abou-El-Ghar ME, Refaie HF et al (2012) Diffusion weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 110(11 Pt B):E622–7. https://doi.org/10.1111/j.1464-410X.2012.11345.x
van der Pol CB, Shinagare AB, Tirumani SH et al (2018) Bladder cancer local staging: multiparametric MRI performance following transurethral resection. Abdom Radiol 43:2412–2423. https://doi.org/10.1007/s00261-017-1449-0
doi: 10.1007/s00261-017-1449-0
Lim CS, Tirumani S, van der Pol CB et al (2019) Use of quantitative T2-weighted and apparent diffusion coefficient texture features of bladder cancer and extravesical fat for local tumor staging after transurethral resection. AJR Am J Roentgenol 212:1060–1069. https://doi.org/10.2214/AJR.18.20718
doi: 10.2214/AJR.18.20718
pubmed: 30860885
Amin M, Edge S, Greene F, et al AJCC Cancer Staging Manual, 8th edn. 2017 New York: Springer.
Compérat E, Oszwald A, Wasinger G et al (2022) Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World J Urol 40:915–927. https://doi.org/10.1007/s00345-021-03831-1
doi: 10.1007/s00345-021-03831-1
pubmed: 34554298
Sauter G, Algaba F, Amin M et al Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of tumours of the urinary system and male genital organs. 2004 IARCC Press: Lyon.
Pecoraro M, Del Giudice F, Magliocca F et al (2022) Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol (NY) Feb;47(2):763–770. https://doi.org/10.1007/s00261-021-03365-5
doi: 10.1007/s00261-021-03365-5
pubmed: 34919160
Hafeez S, Koh M, Jones K et al (2022) Assessing bladder radiotherapy response with quantitative diffusion-weighted magnetic resonance imaging analysis. Clin Oncol (R Coll Radiol) Oct;34(10):630–641. https://doi.org/10.1016/j.clon.2022.04.001
doi: 10.1016/j.clon.2022.04.001
pubmed: 35534398
Takeuchi M, Sasaki S, Ito M et al (2009) Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology Apr;251(1):112–121. https://doi.org/10.1148/radiol.2511080873
doi: 10.1148/radiol.2511080873
pubmed: 19332849
Kobayashi S, Koga F, Yoshida S et al (2011) Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 21:2178–2186. https://doi.org/10.1007/s00330-011-2174-7
doi: 10.1007/s00330-011-2174-7
pubmed: 21688007
Barchetti G, Simone G, Ceravolo I et al (2019) Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol Oct;29(10):5498–5506. https://doi.org/10.1007/s00330-019-06117-8
doi: 10.1007/s00330-019-06117-8
pubmed: 30887202
Huele EH, Veenboer PW, Wessels FJ et al (2023) Value of multiparametric magnetic resonance imaging for local staging of invasive urinary bladder tumours. Urol Oncol Jan;41(1):49.e7-49.e12. https://doi.org/10.1016/j.urolonc.2022.09.026
doi: 10.1016/j.urolonc.2022.09.026
pubmed: 36441069
Wang HJ, Pui MH, Guo Y et al (2014) Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 39(1):135–141. https://doi.org/10.1007/s00261-013-0038-0
doi: 10.1007/s00261-013-0038-0
pubmed: 24072383